Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mallika Lal"'
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-7 (2023)
Abstract Background Professional society practice guidelines conflict regarding their recommendations of dofetilide (DOF) and sotalol (STL) for treatment of arrhythmias in hypertrophic cardiomyopathy (HCM), and supporting data is sparse. We aim to as
Externí odkaz:
https://doaj.org/article/627e232b03c04bb083d693a9b84d706c
Autor:
Mallika, Lal, Chris, Chen, Brittaney, Newsome, Luke, Masha, Samuel A, Camacho, Ahmad, Masri, Babak, Nazer
Publikováno v:
Journal of the American College of Cardiology. 81:100-102
Autor:
Christopher Chen, Mallika Lal, Yunwoo Burton, Hongya Chen, Eric Stecker, Ahmad Masri, Babak Nazer
Background Professional society practice guidelines conflict regarding their recommendations of dofetilide (DOF) and sotalol (STL) for treatment of arrhythmias in hypertrophic cardiomyopathy (HCM), and supporting data is sparse. We aim to assess safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e42c84f14f6f85f54c30e9fc2016ecae
https://doi.org/10.21203/rs.3.rs-2391095/v1
https://doi.org/10.21203/rs.3.rs-2391095/v1
Autor:
Kunihiko Chen, Mallika Lal, Sheila Adams-Sapper, Shantell Nolen, Livia Helena Justo da Silva, Lee W. Riley, Beatriz Meurer Moreira, Grace Fox Donzelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:3281-3289
Enterobacteriaceae strains producing the Klebsiella pneumoniae carbapenemase (KPC) have disseminated worldwide, causing an urgent threat to public health. KPC-producing strains often exhibit low-level carbapenem resistance, which may be missed by aut
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Abstract Background Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for this breast cancer sub
Externí odkaz:
https://doaj.org/article/9b18d12912d54052a89d6ff6e9158442
Autor:
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 10, Pp 748-758 (2019)
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunte
Externí odkaz:
https://doaj.org/article/16930bafa9fd42f6b4ceaac5cf976f1b
Autor:
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the developm
Externí odkaz:
https://doaj.org/article/3069c7c4e0f64562b9cab9bff16d3f3d